Clearmind Medicine Inc. (Nasdaq: CMND) announced the publication in the United States of three patent applications covering novel combinations of lysergic acid diethylamide (LSD), ketamine, and ibogaine with N-acylethanolamines, such as palmitoylethanolamide (PEA).

The applications, according to a press release, address potential therapeutic uses across a range of indications, including depression, post-traumatic stress disorder (PTSD), pain, and substance use disorders.

The publications expand intellectual property developed through Clearmind's ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX), under which NeuroThera's PEA technology is integrated into Clearmind's therapeutic programs. Clearmind previously announced U.S. publication of a separate patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety, and eating disorders.

Clearmind Chief Executive Officer Adi Zuloff-Shani said the combination approach "may offer the potential for an effective and safer treatment paradigm, aiming to achieve therapeutic benefits at lower doses while preserving efficacy."

The company stated its intellectual property portfolio currently consists of 19 patent families, including 32 granted patents. Clearmind is a clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on neuropsychiatric, metabolic, and addiction disorders.